Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|May 18, 2018
Treatment Considerations for Unresectable Locally Advanced NSCLC
Treatment Considerations for Unresectable Locally Advanced NSCLC
Advertisement
- A 64-year-old man presented with shortness of breath and persistent cough of 18 months’ duration; recently, he has experienced chest pain, fatigue, and blood in his sputum. After consulting with his primary care physician, he was referred for oncology evaluation
- Patient history includes
- Current smoker (1/2 pack day)
- Hypertension
- Acute MI at age 60
- Evaluation and follow up testing reveal
- Non-small cell lung cancer in left lung and 2 lymph nodes (Stage IIIa)
- WHO performance status: 1
- Histology: adenocarcinoma
- EFGR, BRAF,andALK/ROS1mutation status: wild-type
- PD-L1 status: ≥25%
- He underwent multidisciplinary evaluation and was not a candidate for surgery; he was treated with chemoradiotherapy:
- Concurrent carboplatin-paclitaxel doublet chemotherapy and radiotherapy (60 Gy)
- Achieved partial response
- He had no disease progression 20 days after his last radiotherapy treatment, and began treatment with durvalumab
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5